% | $
Quotes you view appear here for quick access.

GW Pharmaceuticals plc Message Board

  • mrequity1 mrequity1 Oct 10, 2013 3:38 PM Flag


    Let's say the FDA approves Sativex for cancer pain and MS spasticity. What are the potential revenues? 400,000 MS patients, 100,000 with spasms uncontrolled. $750 million after partner gets their cut ($10,000 yearly cost). Cancer pain is tough to calculate. 400,000 with pain not controlled by opiates, but Sativex can reduce the amount of opiates needed for ALL cancer patients. A wild guess is maybe 1 million patients get Sativex. $6.5 Billion. Let's say $7 billion total and then cut that in half just because. So $3.5 Billion divided by 177 million ordinary shares. So $19 per share multiplied by 12 shares per ADR equals $228 revenue per ADR. Let's cut it in half again because I see through rose colored glasses. $114 in revenue per ADR. Biogen trades at 10 times revenue. Amgen at 5 times. What am I doing wrong?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
87.15-0.15(-0.17%)12:32 PMEDT